Jamie Arnott
Overview
Explore the profile of Jamie Arnott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
242
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yee K, Chen H, Hedley D, Chow S, Brandwein J, Schuh A, et al.
Invest New Drugs
. 2016 Jul;
34(5):614-24.
PMID: 27406088
ENMD-2076 is a novel, orally-active molecule that inhibits Aurora A kinase, as well as c-Kit, FLT3 and VEGFR2. A phase I study was conducted to determine the maximum tolerated dose...
2.
Matulonis U, Lee J, Lasonde B, Tew W, Yehwalashet A, Matei D, et al.
Eur J Cancer
. 2012 Aug;
49(1):121-31.
PMID: 22921155
Purpose: The purpose was to assess the activity and side effect profile of ENMD-2076, an oral anti-angiogenic and anti-proliferative kinase inhibitor, in platinum-resistant recurrent epithelial ovarian cancer (EOC), fallopian tube...
3.
Faris J, Arnott J, Zheng H, Ryan D, Abrams T, Blaszkowsky L, et al.
Invest New Drugs
. 2011 Jul;
30(4):1614-20.
PMID: 21800081
Background: MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. We conducted an open-label Phase II study with MKC-1 in patients...
4.
Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, et al.
Invest New Drugs
. 2011 Jan;
30(3):1039-45.
PMID: 21225315
Background: MKC-1 is an oral cell-cycle inhibitor with broad antitumor activity in preclinical models. Clinical studies demonstrated modest antitumor activity using intermittent dosing schedule, however additional preclinical data suggested continuous...
5.
Bruce J, Eickhoff J, Pili R, Logan T, Carducci M, Arnott J, et al.
Invest New Drugs
. 2010 Dec;
30(2):794-802.
PMID: 21174224
Background: Current treatment for metastatic renal cell cancer with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) have provided improved overall survival, but complete responses are rare. We conducted...
6.
Diamond J, Bastos B, Hansen R, Gustafson D, Eckhardt S, Kwak E, et al.
Clin Cancer Res
. 2010 Dec;
17(4):849-60.
PMID: 21131552
Purpose: ENMD-2076 is a unique orally bioavailable Aurora kinase and VEGFR inhibitor. The purpose of this phase 1 study of ENMD-2076 was to determine the MTD, pharmacokinetic, and pharmacodynamic profiles...
7.
Harrison M, Hahn N, Pili R, Oh W, Hammers H, Sweeney C, et al.
Invest New Drugs
. 2010 May;
29(6):1465-74.
PMID: 20499131
Purpose: 2ME2 (Panzem®) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity. Preclinical data support antitumor activity in prostate cancer. This trial evaluated the efficacy of 2ME2 NCD...
8.
Tevaarwerk A, Holen K, Alberti D, Sidor C, Arnott J, Quon C, et al.
Clin Cancer Res
. 2009 Feb;
15(4):1460-5.
PMID: 19228747
Purpose: 2-methoxyestradiol (2ME2; Panzem) is an endogenous, estradiol-17beta metabolite that at pharmacologic doses exerts antimitotic and antiangiogenic activities. Studies with a 2ME2 capsule formulation showed limited oral bioavailability. We report...